Yamashiro, Hiroyasu http://orcid.org/0000-0003-1778-6735
,
Iwata, Hiroji
Masuda, Norikazu
Yamamoto, Naohito
Nishimura, Reiki
Ohtani, Shoichiro
Sato, Nobuaki
Takahashi, Masato
Kamio, Takako
Yamazaki, Kosuke
Saito, Tsuyoshi
Kato, Makoto
Lee, Tecchuu
Kuroi, Katsumasa
Takano, Toshimi
Yasuno, Shinji
Morita, Satoshi
Ohno, Shinji
Toi, Masakazu
Article History
Received: 19 October 2019
Accepted: 27 January 2020
First Online: 14 February 2020
Compliance with ethical standards
:
: 1 Dr. Yamashiro reports personal fees from Chugai, personal fees from Daiich-Sankyo, personal fees from Pfizer, personal fees from Kyowa Kirin, personal fees from Eisai, personal fees from Eli Lilly, personal fees from Takeda, and personal fees from Taiho outside the submitted work. 2 Dr. Iwata reports grants and personal fees from Chugai during the conduct of the study, and grants and personal fees from Novartis, grants and personal fees from AstraZeneca, grants and personal fees from Pfizer, grants and personal fees from Eli Lilly, grants and personal fees from Daiichi Sankyo, grants from MSD, personal fees from Eisai, grants and personal fees from Kyowa Kirin, and grants from Byer outside the submitted work. Dr Iwata is a member of an organized committee in the Japan Breast Cancer Research Group. 3 Dr. Masuda reports grants, personal fees and other from Chugai, personal fees and other from AstraZeneca, personal fees and other from Pfizer, personal fees and other from Eli Lilly, grants, personal fees and other from Eisai, personal fees and other from Takeda, personal fees and other from Kyowa Kirin, other from MSD, personal fees and other from Novartis, and personal fees and other from Daiichi Sankyo outside the submitted work. 4 Dr. Yamamoto reports other from the Japan Breast Cancer Research Group during the conduct of the study, and other from MSD, other from Eli Lilly, and other from Nippon Kayaku outside the submitted work. 5 Dr. Nishimura reports personal fees from Pfizer, personal fees from Novartis, and personal fees from Chugai outside the submitted work. 6 Dr. Ohtani reports personal fees from Chugai, personal fees from AstraZeneca, personal fees from Eisai, personal fees from Pfizer, and personal fees from Eli Lilly outside the submitted work. 7 Dr. Sato reports personal fees from Chugai, personal fees from Eisai, personal fees from Pfizer, and personal fees from Taiho outside the submitted work. 8 Dr. Takahashi reports personal fees from AstraZeneca, grants and personal fees from Chugai, grants and personal fees from Eisai, personal fees from Eli Lilly, grants and personal fees from Kyowa Kirin, grants and personal fees from Nippon Kayaku, personal fees from Novartis, personal fees from Pfizer, and grants and personal fees from Taiho outside the submitted work. 9 Dr. Kamio has nothing to disclose. 10 Dr. Yamazaki has nothing to disclose. 11 Dr. Saito reports personal fees from Pfizer, personal fees from AstraZeneca, personal fees from Nippon Kayaku, and personal fees from Chugai outside the submitted work. 12 Dr. Kato has nothing to disclose. 13 Dr. Lee has nothing to disclose. 14 Dr. Kuroi reports personal fees from Taiho, Kyowa Kirin, Astellas, Eisai, and Novartis outside the submitted work, and from the Board of directors: Japan Breast Cancer Research Group Organization, Japan Breast Cancer Research Group Association. 15 Dr. Takano reports grants and personal fees from Daiichi Sankyo, grants and personal fees from Kyowa Kirin, grants and personal fees from Eisai, grants from Ono, grants from MSD, grants from Merck Serono, grants from Taiho, grants from Novartis, grants from Chugai, personal fees from Pfizer, and personal fees from Eli Lilly outside the submitted work. 16 Dr. Yasuno has nothing to disclose. 17 Dr. Morita reports personal fees from AstraZeneca, personal fees from Bristol-Myers Squibb, personal fees from Chugai, personal fees from Eisai, personal fees from Eli Lilly, personal fees from MSD, personal fees from Pfizer, and personal fees from Taiho outside the submitted work. 18 Dr. Ohno reports grants and personal fees from Eisai, personal fees from Chugai, personal fees from Pfizer, grants and personal fees from Taiho, personal fees from Nippon Kayaku, personal fees from Kyowa Kirin, personal fees from Novartis, personal fees from AstraZeneca, and personal fees from Eli Lilly outside the submitted work. 19 Dr. Toi reports grants and personal fees from Chugai during the conduct of the study, and grants and personal fees from Taiho, grants and personal fees from Takeda, grants and personal fees from Shimadzu, grants and personal fees from Eisai, grants, personal fees and other from Daiichi Sankyo, personal fees from Yakult, grants, personal fees and other from Kyowa Kirin, personal fees and other from Konica-Minolta, grants and personal fees from Pfizer, personal fees from Eli Lilly, personal fees from MSD, personal fees and other from Genomic Health, grants and personal fees from AstraZeneca, personal fees from Novartis, personal fees from Bayer, personal fees from Sanofi, grants and personal fees from C&C Res Lab, grants and personal fees from Nippon Kayaku, grants from Bizcom Japan, grants from AFI technologies, grants and non-financial support from the Japan Breast Cancer Research Group Association, grants from Astellas, grants from DSK, non-financial support from the Organisation for Oncology and Translational Research, grants and non-financial support from the Kyoto Breast Cancer Research Network, grants from Terumo, and other from BMS outside the submitted work.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.